The effect of cytokine(l-n) on vascular/myocardial function

Carotid body size on CTA: correlation with comorbidities.

Clinical radiology·2013

Incremental programming of atrial anti-tachycardia pacing therapies in bradycardia-indicated patients: effects on therapy efficacy and atrial tachyarrhythmia burden.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2004

Malaligned financial incentives of providers in the treatment of chronic diseases: the case of chronic heart failure.

Congestive heart failure (Greenwich, Conn.)·2002

Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias.

Journal of cardiovascular electrophysiology·2002

Outcome of percutaneous coronary angioplasty (PTCA) performed in a low-volume institution by low-volume operators, evaluated by means of the one-month major adverse cardiac event rate.

Minerva cardioangiologica·2001

Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator.

Circulation·2001

Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy.

Cardiovascular research·2026

Inflammatory cytokines and immune signalling in heart failure: mechanisms, models and emerging therapies.

Cardiovascular research·2026

Timing of food intake impacts cardiovascular and neuroendocrine physiology and risk of disease.

Cardiovascular research·2026

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy.

Cardiovascular research·2026

Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor.

Cardiovascular research·2026

Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis.

Cardiovascular research·2026

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity.

Acta physiologica (Oxford, England)·2026

PCI for in-stent restenosis of an anomalous right coronary artery.

Annales de cardiologie et d'angeiologie·2026

Prophylactic implantation of implantable cardioverter-defibrillator for the primary prevention of sudden cardiac death after myocardial infarction: protocol for systematic review and meta-analysis of randomised controlled trials.

BMJ open·2026

Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study.

BMJ open·2026

Calcium handling in post-infarction arrhythmias - evidence from large animals.

American journal of physiology. Heart and circulatory physiology·2026

Iron Deficiency and Bone Metabolism in Heart Failure.

European journal of heart failure·2026

Related Experiment Videos

The effect of cytokine(l-n) on vascular/myocardial function

Related Concept Videos

Carotid body size on CTA: correlation with comorbidities.

Incremental programming of atrial anti-tachycardia pacing therapies in bradycardia-indicated patients: effects on therapy efficacy and atrial tachyarrhythmia burden.

Malaligned financial incentives of providers in the treatment of chronic diseases: the case of chronic heart failure.

Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias.

Outcome of percutaneous coronary angioplasty (PTCA) performed in a low-volume institution by low-volume operators, evaluated by means of the one-month major adverse cardiac event rate.

Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator.

Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy.

Inflammatory cytokines and immune signalling in heart failure: mechanisms, models and emerging therapies.

Timing of food intake impacts cardiovascular and neuroendocrine physiology and risk of disease.

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy.

Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor.

Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis.

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity.

PCI for in-stent restenosis of an anomalous right coronary artery.

Prophylactic implantation of implantable cardioverter-defibrillator for the primary prevention of sudden cardiac death after myocardial infarction: protocol for systematic review and meta-analysis of randomised controlled trials.

Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study.

Calcium handling in post-infarction arrhythmias - evidence from large animals.

Iron Deficiency and Bone Metabolism in Heart Failure.

Related Experiment Videos

The effect of cytokine(l-n) on vascular/myocardial function

Related Concept Videos

Related Articles